Anti-fibrotic effects of branched-chain amino acids on hepatic stellate cells
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Patients with liver cirrhosis (LC) have low levels of branched-chain amino acids (BCAAs). There is accumulating evidence that BCAAs have anti-fibrotic effects in cirrhosis. This study is aimed to evaluate the effect of BCAAs on the function and phenotype of activated hepatic stellate cells (HSCs). Methods: LX-2, an immortalized human stellate cell line, was used in in vitro experiments. LX-2 cells were exposed to transforming growth factor β1 (TGF-β1) and BCAAs or to valine, leucine, and isoleucine, which are components of BCAAs. Activation of the TGF-β signaling pathway in LX-2 cells was observed using real-time quantitative polymerase chain reaction and Western blotting. Results: The increased expression of snail family transcriptional repressor 1 (SNAI1) was observed in LX-2 cells activated by TGF-β1. After BCAA treatment, its expression was significantly decreased at the mRNA level. The increased expression of Col1α1 and TIMP2 at the mRNA level and alpha smooth muscle actin at the protein level in activated LX-2 cells decreased after BCAA treatment. Among the BCAA components, leucine and valine significantly abrogated TGF-β-induced activation of LX-2 cells. BCAA treatment led to the decreased phosphorylation of Smad2 and p38 proteins, which are markers for Smad and Smad-independent p38 mitogen-activated protein kinase signaling pathways, respectively. Conclusions: BCAA treatment can improve hepatic fibrosis by directly affecting the activated state of hepatic stellate cells through inhibition of the TGF-β signaling pathway. Among BCAA components, leucine and valine mainly abrogated TGF-β- induced activation of HSCs. Our results suggest that BCAA may be used to attenuate the progression of liver fibrosis.
Abstract
Background/Aims: Patients with liver cirrhosis (LC) have low levels of branched-chain amino acids (BCAAs). There is accumulating evidence that BCAAs have anti-fibrotic effects in cirrhosis. This study is aimed to evaluate the effect of BCAAs on the function and phenotype of activated hepatic stellate cells (HSCs). Methods: LX-2, an immortalized human stellate cell line, was used in in vitro experiments. LX-2 cells were exposed to transforming growth factor β1 (TGF-β1) and BCAAs or to valine, leucine, and isoleucine, which are components of BCAAs. Activation of the TGF-β signaling pathway in LX-2 cells was observed using real-time quantitative polymerase chain reaction and Western blotting. Results: The increased expression of snail family transcriptional repressor 1 (SNAI1) was observed in LX-2 cells activated by TGF-β1. After BCAA treatment, its expression was significantly decreased at the mRNA level. The increased expression of Col1α1 and TIMP2 at the mRNA level and alpha smooth muscle actin at the protein level in activated LX-2 cells decreased after BCAA treatment. Among the BCAA components, leucine and valine significantly abrogated TGF-β-induced activation of LX-2 cells. BCAA treatment led to the decreased phosphorylation of Smad2 and p38 proteins, which are markers for Smad and Smad-independent p38 mitogen-activated protein kinase signaling pathways, respectively. Conclusions: BCAA treatment can improve hepatic fibrosis by directly affecting the activated state of hepatic stellate cells through inhibition of the TGF-β signaling pathway. Among BCAA components, leucine and valine mainly abrogated TGF-β- induced activation of HSCs. Our results suggest that BCAA may be used to attenuate the progression of liver fibrosis.
참고문헌 (22)
- Wong MCS, "The growing burden of liver cirrhosis : implications for preventive measures", Hepatol Int, 12, pp.201~203 (2018)
- Rockey DC, "Zakim and Boyer’s Hepatology", pp.2012, Saunders
- Gandhi CR, "Hepatic stellate cell activation and pro-fibrogenic signals", J Hepatol, 67, pp.1104~1105 (2017)
- Holecek M, "Three targets of branched-chain amino acid supplementation in the treatment of liver disease", Nutrition, 26, pp.482~490 (2010)
- Kawaguchi T, "Branched-chain amino acids as pharmacological nutrients in chronic liver disease", Hepatology, 54, pp.1063~1070 (2011)
- Khedr NF, "Branched chain amino acids supplementation modulates TGF-β1", Smad signaling pathway and interleukins in CCl4-induced liver fibrosis, 2017, pp.31, 534~545
- Cha JH, "Branched-chain amino acids ameliorate fibrosis and suppress tumor growth in a rat model of hepatocellular carcinoma with liver cirrhosis", PLoS One, 8, pp.e77899~ (2013)
- Scarpa M, "Snail1 transcription factor is a critical mediator of hepatic stellate cell activation following hepatic injury", Am J Physiol Gastrointest Liver Physiol, 300, pp.G316~G326 (2011)
- Xu J, "TGF-beta-induced epithelial to mesenchymal transition", Cell Res, 19, pp.156~172 (2009)
- Marchesini G, "Nutritional supplementation with branched-chain amino acids in advanced cirrhosis : a double-blind, randomized trial", Gastroenterology, 124, pp.1792~1801 (2003)
- Park JG, "Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease:a Korean nationwide, multicenter, retrospective, observational, cohort study", Medicine(Baltimore), 96, pp.e6580~ (2017)
- Park JG, "Effects of branched-chain amino acid(BCAA)supplementation on the progression of advanced liver disease : a Korean nationwide, multicenter, prospective, observational, cohort study", Nutrients, 12, pp.1429~ (2020)
- Takegoshi K, "Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model", Oncotarget, 8, pp.18191~18205 (2017)
- Dewidar B, "TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019", Cells, 8, pp.1419~ (2019)
- Zhang YE, "Non-smad signaling pathways of the TGF-β family", Cold Spring Harb Perspect Biol, 9, pp.a022129~ (2017)
- Moustakas A, "Non-Smad TGF-beta signals", J Cell Sci, 118, pp.3573~3584 (2005)
- Zhang YE, "Non-Smad pathways in TGF-beta signaling", Cell Res, 19, pp.128~139 (2009)
- 이천주, "Elk-3 Contributes to the Progression of Liver Fibrosis by Regulating the Epithelial-Mesenchymal Transition", Gut and Liver, 11(1), pp.102~111 (2017), 거트앤리버 소화기연관학회협의회
- Zarubin T, "Activation and signaling of the p38 MAP kinase pathway", Cell Res, 15, pp.11~18 (2005)
- Lynch CJ, "Branched-chain amino acids in metabolic signalling and insulin resistance", Nat Rev Endocrinol, 10, pp.723~736 (2014)
- Lynch CJ, "Role of leucine in the regulation of mTOR by amino acids : revelations from structure-activity studies", J Nutr, 131, pp.861~ (2001)[DOI]
- Pereira MG, "Leucine supplementation accelerates connective tissue repair of injured tibialis anterior muscle", Nutrients, 6, pp.3981~4001 (2014)